Patients administered the drug, also known as lysergide, demonstrated consistent improvement on standardized depression scales by the sixth week of treatment. Clinical data indicates that therapeutic effects appear as early as the first week and remain stable for up to 12 weeks. The trial notably achieved an eight-point reduction in symptoms compared to a placebo group.

Chief Executive Rob Barrow characterized the Emerge results as unprecedented, emphasizing that a single dose of the DT120 oral disintegrating tablet provides rapid and durable relief. With these trial outcomes solidified, the company moves closer to a potential regulatory submission for the treatment of major depressive disorder.